

Anti-CD22-NMS249

Chemical Properties

CAS No. :

Formula:

Molecular Weight:

Storage: -20°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	Anti-CD22-NMS249 is an antibody-drug conjugate (ADC) that targets CD22, comprising the humanized anti-CD22 antibody Pinatuzumab, a cleavable linker (Mc-VC-PAB), and the effective payload of DNA topoisomerase II inhibitor PNU-159682. This compound is utilized in the study of non-Hodgkin lymphoma (NHL).
Targets(IC50)	Antibody-Drug Conjugates (ADCs)
In vitro	Anti-CD22-NMS249 effectively inhibits the proliferation of non-Hodgkin lymphoma (NHL) cell lines, displaying IC50 values of 0.058 µg/mL for BJAB.Luc, 0.030 µg/mL for Granta-519, 0.0221 µg/mL for SuDHL4.Luc, and 0.010 µg/mL for WSU-DLCL2.
In vivo	The chemical compound Anti-CD22-NMS249 administered as a single intravenous injection at dosages ranging from 0.5 to 2 mg/kg, induced tumor stasis in four different xenograft models.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481